Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors.
J Infect Dis
; 218(11): 1773-1776, 2018 10 20.
Article
in En
| MEDLINE
| ID: mdl-30010985
ABSTRACT
Bictegravir (BIC) and cabotegravir (CAB) are the latest available HIV integrase inhibitors in clinical trials. The combination of major integrase inhibitor substitutions G140S/Q148H has been shown to confer high-level resistance to the approved integrase inhibitors raltegravir (RAL) and elvitegravir (EVG) but not necessarily dolutegravir (DTG). We assayed recombinant viruses made from patient-derived RNA extracts for resistance phenotype for a panel of viruses containing G140S/Q148H with additional accessory substitutions. The accumulation of multiple integrase substitutions confers high-level resistance to all 5 integrase inhibitors. There is extensive cross-resistance between DTG, BIC, and CAB (r = 0.96-0.97).
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV-1
/
HIV Integrase Inhibitors
/
Drug Resistance, Viral
Limits:
Humans
Language:
En
Journal:
J Infect Dis
Year:
2018
Type:
Article
Affiliation country:
Canada